155 related articles for article (PubMed ID: 1609034)
41. Serum neuroleptic activity, prolactin, and tardive dyskinesia in schizophrenic outpatients.
Csernansky JG; Kaplan J; Holman CA; Hollister LE
Psychopharmacology (Berl); 1983; 81(2):115-8. PubMed ID: 6138793
[TBL] [Abstract][Full Text] [Related]
42. Correlates of rapid neuroleptic response in male patients with schizophrenia.
Petrie EC; Faustman WO; Moses JA; Lombrozo L; Csernansky JG
Psychiatry Res; 1990 Aug; 33(2):171-7. PubMed ID: 2243894
[TBL] [Abstract][Full Text] [Related]
43. Normal prolactin responses in tardive dyskinesia.
Asnis GM; Sachar EJ; Langer G; Halpern FS; Fink M
Psychopharmacology (Berl); 1979; 66(3):247-50. PubMed ID: 43550
[TBL] [Abstract][Full Text] [Related]
44. Increments in plasma homovanillic acid concentrations after neuroleptic discontinuation are associated with worsening of schizophrenic symptoms.
Khan RS; Amin F; Powchik P; Knott P; Goldstein M; Apter S; Kerman B; Jaff S; Davidson M
Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(6):879-84. PubMed ID: 1980541
[TBL] [Abstract][Full Text] [Related]
45. Plasma homovanillic acid and tardive dyskinesia during neuroleptic maintenance and withdrawal.
Kirch D; Hattox S; Bell J; Murphy R; Freedman R
Psychiatry Res; 1983 Jul; 9(3):217-23. PubMed ID: 6137850
[TBL] [Abstract][Full Text] [Related]
46. Plasma homovanillic acid in neuroleptic responsive and nonresponsive schizophrenics.
Duncan E; Wolkin A; Angrist B; Sanfilipo M; Wieland S; Cooper TB; Rotrosen J
Biol Psychiatry; 1993 Oct; 34(8):523-8. PubMed ID: 8274579
[TBL] [Abstract][Full Text] [Related]
47. Differential effect of haloperidol and clozapine on plasma homovanillic acid in elderly schizophrenic patients with or without tardive dyskinesia.
Andia I; Zumarraga M; Zabalo MJ; Bulbena A; Davila R
Biol Psychiatry; 1998 Jan; 43(1):20-3. PubMed ID: 9442340
[TBL] [Abstract][Full Text] [Related]
48. Prolactin response to sodium valproate in schizophrenics with and without tardive dyskinesia.
Monteleone P; Maj M; Ariano MG; Iovino M; Fiorenza L; Steardo L
Psychopharmacology (Berl); 1988; 96(2):223-6. PubMed ID: 3148149
[TBL] [Abstract][Full Text] [Related]
49. Tardive dyskinesia with low-dose, short-term neuroleptic therapy.
Stimmel GL
Am J Hosp Pharm; 1976 Sep; 33(9):961-3. PubMed ID: 984060
[TBL] [Abstract][Full Text] [Related]
50. Etiologic heterogeneity of the psychoses: is there a dopamine psychosis?
Garver DL; Steinberg JL; McDermott BE; Yao JK; Ramberg JE; Lewis S; Kingsbury SJ
Neuropsychopharmacology; 1997 Mar; 16(3):191-201. PubMed ID: 9138435
[TBL] [Abstract][Full Text] [Related]
51. Evolution of plasma homovanillic acid (HVA) in chronic schizophrenic patients treated with haloperidol.
Galinowski A; Poirier MF; Aymard N; Leyris A; Beauverie P; Bourdel MC; Loo H
Acta Psychiatr Scand; 1998 Jun; 97(6):458-66. PubMed ID: 9669519
[TBL] [Abstract][Full Text] [Related]
52. Plasma amine metabolites before and after withdrawal from neuroleptic treatment in chronic schizophrenic inpatients.
Kirch DG; Jaskiw G; Linnoila M; Weinberger DR; Wyatt RJ
Psychiatry Res; 1988 Sep; 25(3):233-42. PubMed ID: 2903509
[TBL] [Abstract][Full Text] [Related]
53. Comparative neurochemical investigation of tardive dyskinesia and neuroleptic-induced chronic parkinsonism.
Arató M; Bagdy G; Perényi A; Béla A
Psychiatry Res; 1984 Apr; 11(4):347-51. PubMed ID: 6146151
[TBL] [Abstract][Full Text] [Related]
54. Elevation of plasma homovanillic acid level can be detected within four hours after initiation of haloperidol treatment.
Davila R; Zumarraga M; Perea K; Andia I; Friedhoff AJ
Arch Gen Psychiatry; 1987 Sep; 44(9):837-8. PubMed ID: 3632258
[No Abstract] [Full Text] [Related]
55. Association of plasma homovanillic acid with behavioral symptoms in patients diagnosed with dementia: a preliminary report.
Sweet RA; Pollock BG; Mulsant BH; Rosen J; Lo KH; Yao JK; Henteleff RA; Mazumdar S
Biol Psychiatry; 1997 Dec; 42(11):1016-23. PubMed ID: 9386853
[TBL] [Abstract][Full Text] [Related]
56. Prolactin levels and effects of neuroleptics.
Brown WA
Psychosomatics; 1983 Jun; 24(6):569-74, 577-81. PubMed ID: 6136065
[No Abstract] [Full Text] [Related]
57. Differential effects of haloperidol on negative symptoms in drug-naive schizophrenic patients: effects on plasma homovanillic acid.
Labarca R; Silva H; Jerez S; Ruiz A; Forray MI; Gysling K; Andres ME; Bustos G; Castillo Y; Hono J
Schizophr Res; 1993 Mar; 9(1):29-34. PubMed ID: 8461269
[TBL] [Abstract][Full Text] [Related]
58. Prediction of short-term changes in symptom severity by baseline plasma homovanillic acid levels in schizophrenic patients receiving clozapine.
Sumiyoshi T; Hasegawa M; Jayathilake K; Meltzer HY
Psychiatry Res; 1997 Mar; 69(2-3):113-21. PubMed ID: 9109179
[TBL] [Abstract][Full Text] [Related]
59. Pharmacodynamics and pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patients.
Chang WH; Lin SK; Jann MW; Lam YW; Chen TY; Chen CT; Hu WH; Yeh EK
Biol Psychiatry; 1989 Jul; 26(3):239-49. PubMed ID: 2742942
[TBL] [Abstract][Full Text] [Related]
60. Measurement of plasma homovanillic acid concentrations in schizophrenic patients.
Kaminski R; Powchick P; Warne PA; Goldstein M; McQueeney RT; Davidson M
Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(3):271-87. PubMed ID: 2193315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
